The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 24th year, is a premier multidisciplinary CME conference, recognized as the leading global forum on CardioRenalMetabolism- diabetes, obesity, lipids, cardiovascular, kidney, and liver diseases. The Congress uniquely integrates basic science with clinical practice under its guiding theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science. Today.

​

Participants are able to earn up to 27 CME & ABIM-MOC credits.

​

The WCIRDC program offers a unique convergence of basic, translational and clinical science. For over two decades, it has brought together physicians, clinicians, researchers, and other healthcare professionals from around the world to participate in an exclusive program that seamlessly bridges the latest discoveries from bench to bedside and back again.

​

Frequently described with the phrase, “I heard it first at WCIRDC,” the Congress provides an unparalleled opportunity to engage directly with distinguished global faculty in an intimate setting. This dynamic exchange propels understanding of metabolic diseases and advances the exploration of emerging therapeutic approaches.

​

Since the seminal work of Dr. Gerald Reaven, which crystallized the interplay among insulin resistance, diabetes, obesity, and cardiovascular disease, the scope of the Congress has significantly expanded under the leadership of Yehuda Handelsman. It now extends to the kidney, liver, HF, brain, cancer, and beyond.

​

The program encompasses key areas such as dyslipidemia, atherosclerosis, hypertension, hypercoagulation, and inflammation, with a strong focus on the intricate connections across Obesity-Diabetes–Cardio–Renal and Metabolic Diseases.

​

In addition, the agenda highlights the latest updates on pharmaceutical interventions The goal is to foster a comprehensive understanding of novel therapeutic approaches, and the development of integrated clinical management strategies in metabolic disorders and comorbidities.

​

To bridge the gap between research and clinical practice, each session will be followed by live Q&A and panel discussions to explore the clinical implications of new findings. Enhanced opportunities for interaction with faculty and peers will also be built into the program through extended breaks and social events.

​

The Congress showcases cutting-edge abstracts from both emerging investigators and world-renowned leaders. The highest-ranked abstracts will be selected for oral presentation, highlighting innovative contributions to the field.

​

This year’s recipient of the Gerald Reaven Distinguished Leader Award is George Grunberger, MD - Chairman of the Grunberger Diabetes and Endocrinology, with the prestigious he will deliver the keynote lecture: Quo Vadis, Insulin Resistance?

​

In addition, Clinical Workshops and Meet-the-Experts sessions will provide small-group learning and intimate, face-to-face engagement with some of the most respected leaders in metabolic disease research and practice.

PROGRAM OBJECTIVES

The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, ASCVD,  HF, CKD and the liver, focusing on insulin resistance, obesity, the gut, the brain, the kidney and the heart. The goal is to understand pathophysiology and to develop appropriate comprehensive clinical management plans.

​

Upon completion of this meeting, participants should be able to:

​

• Describe the relationship between insulin resistance, obesity, diabetes, kidney disease, and heart disease

• Discuss evolving concepts, diagnosis, and therapeutic interventions for MASLD/MASH

• Discuss strategies for obesity management and prevention of complications

• Implement best practices for the prevention and management of CKD, HF, and ASCVD

• Describe the benefits of GLP1-RA–based therapy alone and in combination

• Explain the impact of insulin resistance, Obesity and Diabetes in CKD, HF, and CVD

• Understand the definition and diagnose the causes of resistant HTN and contemporary approaches to management

• Design therapeutic approach for patients with multiple cardiorenalmetabolic conditions focus on agents with broad effects across the spectrum of these comorbidities

• Utilize technology, digital health and AI to enhance the effectiveness of therapeutics

• Recognize the important role of adrenal hormones—specifically aldosterone and cortisol—in the development of Resistant diabetes, resistant hypertension, and impact on heart and kidney diseases

​

TARGET AUDIENCE
This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/GYNs, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.

​

​

Best Regards,